This application to continue as the Statistical and Data Management Center (SDMC) for the Microbicide Trials Network (MTN) is one of three applications comprising the Leadership Group of the MTN. To address the overall scientific goal described in RFA-AI-12-008, the development of a safe and effective microbicide for HIV prevention, the MTN SDMC scientific agenda includes the following aims: 1. Ensure the collection of complete, high quality data by providing state-of-the-art secure data management systems and training according to best data and clinical management practices. 2. Provide statistical and epidemiologic leadership and support throughout the protocol development and implementation process, including study design, monitoring and analysis and reporting. 3. Develop and implement innovative statistical and epidemiological approaches to improve the scientific understanding of HIV risk, how microbicides reduce this risk and how this reduction may be modified or influenced by biological and behavioral factors. The MTN SDMC has extensive experience in the design, conduct and analysis of HIV prevention studies. The scientific leadership of the faculty engaged in the MTN SDMC will ensure MTN trials are designed to obtain reliable answers to the most pressing questions in microbicides development. To help guide the complex task of developing and testing integrated strategies for HIV prevention, we will engage in a collaborative program of mathematical modeling. New microbicides will be developed through a sequence of Phase 1, 2 and 3 trials. Our systems for data collection, management, monitoring and analysis are all well tested and in accordance with ICH guidelines. We will support the leadership group with timely and accurate reporting of MTN studies throughout follow-up to study completion. We will continue to support the MTN LC program through coordination of specimens and assay results, and with statistical analysis and methods development. SCHARP statisticians will develop and deploy statistical methodologies to increase the efficiency and rigor of the proposed program of microbicide trials.

Public Health Relevance

The HIV/AIDS epidemic continues to affect many regions of the world and HIV vulnerable populations are in need of safe, cost-effective, convenient and discreet methods to protect themselves from acquiring HIV. Microbicides have the potential to deliver this protection. The MTN SDMC will provide the highest quality of clinical trial design, data management and statistical analysis to ensure scientifically sound and robust results for MTN trials.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-RRS-A (S1))
Program Officer
Black, Roberta J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Seaton, Kelly E; Ballweber, Lamar; Lan, Audrey et al. (2014) HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities. PLoS One 9:e101863
Balkus, Jennifer E; Richardson, Barbra A; Rabe, Lorna K et al. (2014) Bacterial vaginosis and the risk of trichomonas vaginalis acquisition among HIV-1-negative women. Sex Transm Dis 41:123-8
Cranston, Ross D; Hoesley, Craig; Carballo-Dieguez, Alex et al. (2014) A randomized male tolerance study of dapivirine gel following multiple topical penile exposures (MTN 012/IPM 010). AIDS Res Hum Retroviruses 30:184-9
Dimitrov, Dobromir; Kuang, Yang; Mâsse, Benoît R (2014) Assessing the Public Health impact of HIV interventions: the critical role of demographics. J Acquir Immune Defic Syndr 66:e60-2
Herold, Betsy C; Dezzutti, Charlene S; Richardson, Barbra A et al. (2014) Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1. J Acquir Immune Defic Syndr 66:65-73
Khanna, Aditya S; Dimitrov, Dobromir T; Goodreau, Steven M (2014) What can mathematical models tell us about the relationship between circular migrations and HIV transmission dynamics? Math Biosci Eng 11:1065-90
McGowan, Ian; Hoesley, Craig; Cranston, Ross D et al. (2013) A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007). PLoS One 8:e60147
Hendrix, Craig W; Chen, Beatrice A; Guddera, Vijayanand et al. (2013) MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One 8:e55013